Merck & Company, Inc. company logo

# 1st Gen Model Merck & Company, Inc. Pharmaceutical preparations

Subscribe >> Deal exit on
Aug. 22, 2017
Deal entry on
Aug. 22, 2017
0.39%Expected margin
66.00% successful of 50 deals
$61.97 Last close price
at 21-aug-2017


Model's trade recommendations 4.21% Return for period

6.27% Annual return

$168.19B Market Cap

β 0.80  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 4.21%
52wk return 1.07%
52wk Range
Sortino ratio 1.46
Sharpe ratio 1.01
Norm. RMSE 0.24%
Downside risk 4.05%
Volatility 5.87%
  • 1.88 (3.06%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Merck & Company, Inc. (MRK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 10, 2014.

Market data for MRK model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 2734M
P/E 15.97
Shares Outstanding 2735M
% Held by Insiders 0.05%
% Held by Institutions 73.46%
EPS (last reported FY) $3.78
EPS (last reported Q) $1.01
EPS, estimated (last reported Q) $0.87
Total revenues $40 B
Net income $4 B